What is the BRAVOTM Model?
Application Area includes but not limited to:
The BRAVO model can be linked to a health system/ insurance plan to conduct risk stratification in the covered people with diabetes. Each patient will be assigned to the corresponding risk strata based on their predicted short-term/long-term risks of cardiovascular diseases and mortality. Thus, the BRAVO model can help the health system/ insurance to maximize the effectiveness of diabetes management by pinpointing the high-risk population.
The BRAVO simulation model can extrapolate the short-term (e.g., six-month) efficacy trials to a long-term cardiovascular outcomes trial (CVOT). It can serve as the real-world extension of the existing trials to explore the long-term benefit of the corresponding treatments.
COST EFFECTIVENESS ANALYSIS
It can be applied to conduct classic pharmacoeconomics evaluation, comparing the cost-effectiveness between alternative drugs/treatments.
The BRAVO model can be used to evaluate the benefit and cost-effectiveness of a policy/program/guideline. We have applied the model to evaluate the Medicare PartD Senior Saving Mode, the ADA’s diabetes insight program, and the American College of Physicians’ guidance statement on glycemic control.
About BRAVO™ MODEL
bravo™ model compares to other diabetes models
BW and BMI
utility and cost
Publications and Presentations
- Shao, Hui, Lizheng Shi, and Vivian A. Fonseca. “Using the BRAVO Risk Engine to Predict Cardiovascular Outcomes in Clinical Trials With Sodium–Glucose Transporter 2 Inhibitors.” Diabetes Care 43, no. 7 (July 1, 2020): 1530–36. https://doi.org/10.2337/dc20-0227.
- Shao, Hui, Vivian Fonseca, Roy Furman, Luigi Meneghini, and Lizheng Shi. “Impact of Quality Improvement (QI) Program on 5-Year Risk of Diabetes-Related Complications: A Simulation Study.” Diabetes Care 43, no. 11 (November 1, 2020): 2847–52. https://doi.org/10.2337/dc20-0465.
- Shao, Hui, Shuang Yang, Charles Stoecker, Vivian Fonseca, Dongzhe Hong, and Lizheng Shi. “Addressing Regional Differences in Diabetes Progression: Global Calibration for Diabetes Simulation Model.” Value in Health 22, no. 12 (December 1, 2019): 1402–9. https://doi.org/10.1016/j.jval.2019.08.007.
- Shao, Hui, Shuang Yang, Vivian Fonseca, Charles Stoecker, and Lizheng Shi. “Estimating Quality of Life Decrements Due to Diabetes Complications in the United States: The Health Utility Index (HUI) Diabetes Complication Equation.” PharmacoEconomics 37, no. 7 (July 1, 2019): 921–29. https://doi.org/10.1007/s40273-019-00775-8.
- Shao, Hui, Vivian Fonseca, Charles Stoecker, Shuqian Liu, and Lizheng Shi. “Novel Risk Engine for Diabetes Progression and Mortality in USA: Building, Relating, Assessing, and Validating Outcomes (BRAVO).” PharmacoEconomics 36, no. 9 (September 1, 2018): 1125–34. https://doi.org/10.1007/s40273-018-0662-1.
- Si L, Willis M, Shao H, et al. “Evaluating the Ability of Economic Models of Diabetes to Simulate New Cardiovascular Outcomes Trials: A Report on the Ninth Mount Hood Diabetes Challenge.” Value in Health, August 6, 2020. https://doi.org/10.1016/j.jval.2020.04.1832.
- Shao, Hui, Hamed Kianmehr, Piaopiao Li, Vivian Fonseca, and Lizheng Shi. “364-P: Efficacy of IGlarLixi on Five-Year Risk of Diabetes-Related Complications: A Simulation Experiment.” Diabetes 70, no. Supplement 1 (June 1, 2021). https://doi.org/10.2337/db21-364-P.
- Kianmehr, Hamed, Ping Zhang, Meda E. Pavkov, Kai M. Bullard, Vivian Fonseca, Lizheng Shi, and Hui Shao. “139-OR: ADA Presidents’ Select Abstract: Potential Gains in Life Expectancy (LE) Associated with Achieving Treatment Goals in People with Type 2 Diabetes (T2D) in the U.S.” Diabetes 70, no. Supplement 1 (June 1, 2021). https://doi.org/10.2337/db21-139-OR.
- Shao, Hui, Hamed Kianmehr, Lizheng Shi, Vivian Fonseca, and Joshua D. Brown. “140-OR: Projected Impact of the Medicare Part D Senior Savings Model (SSM) on Diabetes-Related Health and Economic Outcomes among Insulin Users Covered by Medicare.” Diabetes 70, no. Supplement 1 (June 1, 2021). https://doi.org/10.2337/db21-140-OR.